Our lead candidates
The Galenicap portfolio is based on two cornerstones: [1] medical need first, technology second, and [2] use patents are nice-to-have, product patents are critical
GLCP-003-1
Cardiovascular
Reformulation and development of an oral extended-release formulation of a known compound for the treatment of VT/VF and LQTS
Market size (TAM): EUR76M to EUR455M
GLCP-046-1
Cardiovascular (stroke)
Repurposing and development of an oral formulation of a known compound for neuroprotection of stroke-induced brain damage, with a focus on rapid administration
Market size (TAM): EUR171M to EUR1.8B
GLCP-079-1
Infectious Diseases
Reformulation and development of high-dose, targeted formulation of a known compound for the treatment of drug-resistant M. abscessus infection
Market size (TAM): EUR179M to EUR1.7B
GLCP-009-1
Oncology
Reformulation and development of a target release formulation of a known compound for the treatment of peritoneal cancer
Market size (TAM): EUR50M to EUR100M
GLCP-108-1
Infectious diseases
Reformulation and development of a known compound for the treatment of Aspergillus infections
Market size (TAM): depending on clinical positioning
GLCP-013-1
Oncology
Development of an oral fixed dose combination of two known compounds for the treatment of castrate-resistant prostate cancer (CRPC)
Market size (TAM): depending on clinical positioning
GLCP-008-1
Central Nervous Diseases
Reformulation and development of a high-concentration intramuscular (IM) formulation of a known compound the treatment of Treatment-Resistant Schizophrenia (TRS)
Market size (TAM): EUR73M
GLCP-051-1
Women's Health
Reformulation and development of a target and sustained (once-monthly) release formulation of known compound for the treatment of endometriosis and related diseases
Market size (TAM): EUR2B+
GLCP-086-1
Cardiovascular (stroke)
Development of a novel formulation of a known compound for neuroprotection of ischemic stroke-induced brain damage in MCA stroke patients undergoing thrombectomy
Market size (TAM): EUR549M to EUR1.1B
GLCP-048-1
Cardiovascular (stroke)
Repurposing and development of an oral formulation of a known compound for the prevention of secondary stroke in high-risk patients, with low-bleeding risk and a novel mechanism of action
Market size (TAM): EUR555M to EUR3.2B
GLCP-007-1
Gastro-intestinal disease
Development of targeted, extended release formulation of a known compound for the treatment of gastro-intestinal related infections
Market size (TAM): depending on clinical positioning
Strong focus on product innovation
Most of our value-added medicine (VAM) development programs originate from collaborations with prestigious universities, medical schools and smaller specialty pharma firms. In recent years, drug repurposing has indeed gained substantial traction due to its budget constraints and expedited development timelines, particularly compared to new NCE or biotech product development. However, reliance only on existing, commercially available dosage forms presents challenges, as protection through 'use patents' is rather limited. By incorporating a drug reformulation strategy, Galenicap unlocks the potential to create unique products with a robust intellectual property (IP) position that aligns perfectly with the new therapeutic indications being targeted.
Multidisciplinary screening process
Before embarking on new development programs, candidate projects undergo a thorough evaluation process. This includes the validation of clinical necessity and Target Product Profile, an assessment of technical feasibility, scrutiny of the IP landscape and market exclusivity, examination of the regulatory pathway, formulation of an appropriate go-to-market strategy, and exploration of opportunities for commercialization or partnerships. This comprehensive procedure involves close collaboration with external experts and insights from clinical KOLs. Furthermore, the evaluation process takes into account factors such as development costs, portfolio diversification, and a strong emphasis on addressing unmet clinical needs. The objective is to efficiently advance products, maintain a well-balanced portfolio, and prioritize impactful contributions to healthcare.
